Clinical Trials Sponsored by Romark Laboratories L.C.

Total 137 results

Romark Laboratories L.C.

Completed

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C (STEALTHC-2)

Chronic Hepatitis C

United States
Romark Laboratories L.C.

Not yet recruiting

Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness

COVID-19
Romark Laboratories L.C.

Completed

Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

Influenza

United States
Romark Laboratories L.C.

Completed

A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza

Influenza

United States, Australia, Puerto Rico
Romark Laboratories L.C.

Terminated

Study of Nitazoxanide in Adults With Acute Uncomplicated Influenza

Influenza

United States
Romark Laboratories L.C.

Completed

Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

Influenza

United States, Australia, Belgium, Canada, New Zealand
Romark Laboratories L.C.

Completed

Efficacy Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in Children

Rotavirus Infection | Viral Gastroenteritis Due to Rotavirus

Egypt
Romark Laboratories L.C.

Completed

Nitazoxanide for the Treatment of Prolonged Diarrhea in Children

Diarrhea

Peru
Romark Laboratories L.C.

Completed

Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C (STEALTHC-1)

Chronic Hepatitis C

Egypt
Romark Laboratories L.C.

Completed

Study of Nitazoxanide in the Treatment of Chronic Hepatitis C

Chronic Hepatitis C

Egypt
Romark Laboratories L.C.

Completed

Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis

Clostridium Difficile

United States
Romark Laboratories L.C.

Completed

Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis C

Chronic Hepatitis C

Egypt
Romark Laboratories L.C.

Completed

Study of Nitazoxanide in the Treatment of Amebiasis in Adults and Adolescents

Amebiasis

Egypt
Romark Laboratories L.C.

Not yet recruiting

Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness

COVID-19
Romark Laboratories L.C.

Recruiting

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

Rhinovirus | Enterovirus

United States
Romark Laboratories L.C.

Completed

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19

COVID-19

United States
Romark Laboratories L.C.

Active, not recruiting

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection

COVID-19 | Viral Respiratory Illnesses

United States
Romark Laboratories L.C.

Completed

Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B

Chronic Hepatitis B

Singapore
Romark Laboratories L.C.

Terminated

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)

COVID-19 | Viral Respiratory Illnesses

United States
Romark Laboratories L.C.

Completed

Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

Rhinovirus | Enterovirus

United States, Puerto Rico
Romark Laboratories L.C.

Completed

Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

Influenza

United States, Australia, Puerto Rico
Romark Laboratories L.C.

Terminated

Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease

Clostridium Infections

United States
Romark Laboratories L.C.

Completed

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients (STEALTHC-3)

Chronic Hepatitis C

United States
Romark Laboratories L.C.

Terminated

Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease

Crohn's Disease

United States
Romark Laboratories L.C.

Completed

Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in Children

Rotavirus Infection | Norovirus Infection | Adenoviridae Infection
Romark Laboratories L.C.

Completed

4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C

Chronic Hepatitis C

Egypt
Romark Laboratories L.C.

Completed

Study of Nitazoxanide in the Treatment of Amebiasis in Children

Amebiasis

Egypt
Romark Laboratories L.C.

Unknown

A Study to Evaluate the Use of Nitazoxanide to Treat Cryptosporidiosis

HIV Infections | Cryptosporidiosis

United States
Romark Laboratories L.C.

Terminated

Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients

HIV Infections | Cryptosporidiosis

United States
Impax Laboratories, LLC

Completed

Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations

Parkinson Disease

United States, Czechia, France, Germany, Italy, Poland, Spain, United Kingdom
Wren Laboratories LLC

Enrolling by invitation

RegisterNET - A Registry for Neuroendocrine Tumors in the USA (RegisterNET)

Neuroendocrine Tumor | Neuroendocrine Carcinoma | Carcinoid

United States
Impax Laboratories, LLC

Completed

A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations

Parkinson's Disease (Disorder)

United States, Czechia, France, Italy, Spain, Germany, Poland, United Kingdom
Advenchen Laboratories, LLC

Available

Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)

Gynecologic Cancer | Sarcoma,Soft Tissue
Diatherix Laboratories, LLC

Suspended

TEM-PCR™ Prospective Clinical Utility Study

Upper Resp Tract Infection

United States
Paradigm Laboratories LLC

Unknown

COVID-19 Tests With Saliva Specimens

Covid19

United States
Impax Laboratories, LLC

Completed

A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis

Multiple Sclerosis | Spasticity

United States
Impax Laboratories, LLC

Completed

IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis

Multiple Sclerosis

United States, Canada, Estonia, Latvia, Ukraine
Impax Laboratories, LLC

Completed

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066

Parkinson's Disease

Germany, United States, France, Italy
Impax Laboratories, LLC

Completed

Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease

Parkinson's Disease

United States
Impax Laboratories, LLC

Completed

Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)

Restless Legs Syndrome

United States
Neuvosyn Laboratories, LLC

Enrolling by invitation

A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary Hypothyroidism

Hypothyroidism

United States
Wren Laboratories LLC

Active, not recruiting

Surgical Intervention and the NETest (NETest_Sx)

Neuroendocrine Tumor | Gastroenteropancreatic

Italy
Impax Laboratories, LLC

Completed

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

Parkinson's Disease

United States, Canada, France, Germany, Poland, Romania, Spain, Ukraine
Impax Laboratories, LLC

Completed

An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease

Parkinson's Disease

United States, Canada, Estonia, Latvia, Lithuania, Romania, Ukraine, Germany, Poland, Spain
Impax Laboratories, LLC

Completed

A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease

Parkinson's Disease

United States
Impax Laboratories, LLC

Completed

A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease (APEX-PD)

Parkinson's Disease

United States, Canada, Estonia, Latvia, Lithuania, Romania, Ukraine
Advenchen Laboratories, LLC

Terminated

Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) (AL3818)

Cervical Cancer | Ovarian Cancer | Endometrial Cancer

United States
Impax Laboratories, LLC

Completed

A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects

Cardiac Repolarization in Healthy Subjects

United States
Advenchen Laboratories, LLC

Active, not recruiting

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (APROMISS)

Leiomyosarcoma | Synovial Sarcoma | Alveolar Soft Part Sarcoma | Soft-Tissue Sarcoma

United States, United Kingdom, Spain, China, Italy
Advenchen Laboratories, LLC

Active, not recruiting

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (AL3818)

Fallopian Tube Carcinoma | Cervical Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

Korea, Republic of, Spain, United States, United Kingdom, China, Italy

3

Subscribe